No Data
No Data
Dimerix Appoints Nonexecutive Chair
Biopharmaceutical company Dimerix (ASX:DXB) appointed Mark Diamond as nonexecutive chair, effective Dec. 1. In May, Diamond retired from Antisense Therapeutics (ASX:ANP) as managing director and chief
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels
Antisense Therapeutics (ASX:ANP) established an unmarketable parcel share sale facility for shareholders who hold fully paid ordinary shares valued at less than AU$500, the biotechnology company said
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million
Antisense Therapeutics (ASX:ANP) completed its recent share purchase plan, which raised gross proceeds of about AU$3.3 million, the biotechnology company said Monday. The SPP, launched July 28, will b
Antisense Therapeutics Price Target Cut 12% to A$0.23/Share by Morgans
Antisense Therapeutics Price Target Cut 12% to A$0.23/Share by Morgans
Antisense Therapeutics Appoints CEO/Managing Director
Antisense Therapeutics (ASX:ANP) appointed James Garner as chief executive officer and managing director, effective Monday, the biotechnology company said the same day. Garner has more than 20 years o
ASX Closes 0.85% Higher: Rio Tintos Half-year Profit Gets Slammed
Rio Tinto's (ASX:RIO) half-year profit fell 34% due to weaker commodity prices. The $US5.7 billion underlying result and dividend missed analyst estimates. Australian iron ore dominated the result, bu
No Data